Highly differentiated follicular carcinoma of ovary: Use of imprint cytology at intraoperative consultation

Dobi, Alice; Kim, Sun A.; Zhang, Ming; Iames, Edward S.; Lamzabi, Ihab

doi:10.1002/dc.24360

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PRISMA flow diagram is presented in Figure 1 , and schematically describes the selection process and outcome. Finally, a total of 16 studies were included in the present analysis [ 10 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ].…”

Section: Resultsmentioning

confidence: 99%

Highly Differentiated Follicular Carcinoma of Ovarian Origin: A Systematic Review of the Literature

et al. 2022

View full text Add to dashboard Cite

(1) Background: Highly differentiated follicular carcinoma of ovarian origin (HDFCO) is an extremely uncommon neoplasm, associated with struma ovarii. There are scarce cases reported in the literature and, subsequently, no reliable conclusions on its pathophysiology, treatment, and prognosis can be drawn. The goal of this study is to enrich the literature on the topic by adding our own experience with a case, and simultaneously accumulate all cases published up to date. (2) Methods: The present review was performed in accordance with the guidelines for systematic reviews and meta-analyses (PRISMA). PubMed (1966–2022), Scopus (2004–2022), and Clinicaltrials.gov databases were screened for relevant articles published up to July 2022. (3) Results: Twenty patients with HDFCO were identified. The included patients were aged 47.15 years (range 24–74). The predominant origin was ovarian (60%) and extraperitoneal spread was confirmed in 15% of the cases. Surgical treatment varied from conservative to radical (35.3% vs. 41.2%, respectively) and the administration of supplementary therapy and thyroidectomy was not universal. Combined thyroidectomy/radioactive iodine therapy was applied in just 62.5% of the reported cases. There was one patient who demonstrated disease recurrence and lives with the disease. No disease related morbidity was reported. (4) Conclusions: HDFCO represents a low-grade malignant tumor, whose rarity does not allow for reliable conclusions. Standard treatment including complete surgical excision and supplementary treatment seems to offer a favorable prognosis in selected cases.

show abstract

Section: Resultsmentioning

confidence: 99%

Highly Differentiated Follicular Carcinoma of Ovarian Origin: A Systematic Review of the Literature

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/diagnostics13091581/s1, Figure S1: The detailed inclusion and exclusion process in this study (PRISMA flow diagram); Figure S2: The tumor located at the right hepatorenal recess (patient 1); Figure S3: Intraoperative findings revealed a 2 cm smooth-round pink nodule at the right anterior peritoneum (patient 2); Figure S4: Intraoperative view of the mesorectal tumor (patient 3); Table S1. The summary of patients with peritoneal strumosis [6,[8][9][10][11]15,[18][19][20][22][23][24][25][26].…”

Section: Supplementary Materialsmentioning

confidence: 99%

Clinical Characteristics, Treatment, and Outcomes of Peritoneal Strumosis: A Report of Three Cases and Systematic Review

Wang

Hong

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Benign struma ovarii (SO) has a probability of metastasis named “peritoneal strumosis”, which is extremely rare, such that the specific clinical characteristics, treatment options, and survival outcomes remain unclear. We screened three cases of peritoneal strumosis among 229 cases of SO treated in our hospital. Case 1 was a 36-year-old woman with extensive peritoneal seedings at initial presentation. The second one was a 49-year-old with trocar site implant 11 years after laparoscopic adnexectomy. Case 3 was a 45-year-old woman who had an isolated lesion at the anterior surface of the rectum after laparoscopic ovarian cystectomy for SO 14 years ago. These three patients underwent surgery without any adjuvant treatment and remained disease-free after 30 to 68 months. A systematic review was then conducted and another 16 cases were identified. More than half (10/19, 52.6%) of the patients had previous SO-related ovarian surgery. The median interval between prior SO-related surgery and the initial presentation of peritoneal strumosis was 10.0 years; both regional and distant metastasis, even in the liver, lung, and heart, could also be affected. Surgery was the mainstay therapy (18/19, 94.7%), in which six patients (6/19, 31.7%) were treated with total thyroidectomy (TT) followed by radioiodine (RAI) therapy. Postoperative chemotherapy was only applied in one patient, and the last one only received a diagnostic biopsy without further treatment. Recurrence was noted in two patients with a median recurrence-free survival of 12 years, where surgical excision and RAI were then performed. No death occurred after a mean follow-up of 53 months, where 12 patients achieved no evidence of disease and five were alive with the disease. Peritoneal strumosis has unpredictable biological behaviors and the crude incidence is approximately 1.3% in SO. Patients with peritoneal strumosis have excellent survival outcomes, irrespective of different treatment strategies employed. Surgery with personalized RAI should be preferred and long-term close monitoring is recommended.

show abstract

Malignant struma ovarii: From case to analysis

Ayhan

Kılıç

Ersak

et al. 2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim: To evaluate the clinico-pathologic features, treatment options, prognostic factors, and survival outcomes of malignant struma ovarii based on a systematic literature review in association with our case study. Methods: A systematic review of the medical literature was performed to identify articles about malignant struma ovarii from January 1983 until July 2020. We evaluated 178 cases. Results: The 5-year progression-free survival (PFS) and overall survival (OS) of the entire cohort was 72.5% and 91%, respectively. In univariate analysis, younger age (<43 years), whole strumal cyst diameter >95 mm, presence of a histologic type other than papillary classic-type thyroid carcinoma within the tumor and lymphovascular space invasion were related to poor PFS. Patients who received radioactive iodine ablation (RIA) before the treatment failure had significantly higher PFS than those who did not receive RIA (94.9% vs. 64.8%, p = 0.041, respectively). In univariate analysis, PFS was significantly higher in patients who underwent gynecologic surgery followed by thyroidectomy and RIA compared with those who had surgical treatment only (94.5% vs. 64.3%, p = 0.05, respectively). However, this result could not be identified as an independent prognostic factor in multivariate analysis (p = 0.207). Younger age and absence of capsular involvement were related to significantly increased OS. Histologic type was the only independent prognostic factor for PFS (hazard ratio: 3.30, 95% confidence interval: 1.122-9.748; p = 0.030) Conclusion: The most common histologic subtype was the papillary classic type. The presence of a histologic type other than the classic papillary thyroid carcinoma within the tumor was an independent adverse prognostic factor.

show abstract

Highly differentiated follicular carcinoma of ovary: Use of imprint cytology at intraoperative consultation

Cited by 4 publications

References 7 publications

Highly Differentiated Follicular Carcinoma of Ovarian Origin: A Systematic Review of the Literature

Highly Differentiated Follicular Carcinoma of Ovarian Origin: A Systematic Review of the Literature

Clinical Characteristics, Treatment, and Outcomes of Peritoneal Strumosis: A Report of Three Cases and Systematic Review

Malignant struma ovarii: From case to analysis

Contact Info

Product

Resources

About